Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia

BMJ Open

Volumn 3, Issue 7, 2013, Pages

  Gao, Yang ^a,b   O'Caoimh, Rónán ^a   Healy, Liam ^a   Kerins, David M ^b,c   Eustace, Joseph ^c   Guyatt, Gordon ^d   Sammon, David ^b   Molloy, D William ^a,d  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c MERCY UNIVERSITY HOSPITAL   (Ireland)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; QUICK MILD COGNITIVE IMPAIRMENT SCORE; SCORING SYSTEM; UNIVERSITY HOSPITAL;

EID: 84883389617     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-002881     Document Type: Article

References (65)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366: 2112-17. (Pubitemid 41797645)
2. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002;23: 213-31. (Pubitemid 34508073)
3. Whitmer R, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64: 277-81.
4. Breteler MMB, Claus JJ, Grobbee DE, et al. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam study. BMJ 1994;308: 1604-8. (Pubitemid 24181869)
5. Rozzini L, Vicini Chilovi B, Trabucchi M, et al. Antihypertensive medications influence the rate of conversion from mild cognitive impairment to Alzheimer disease. Arch Neurol 2008;65:993.
6. Duron E, Rigaud AS, Dubail D, et al. Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. Am J Hypertens 2009;22: 1020-4.
7. Ligthart SA, Van Charante EPM, Van Gool WA, et al. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag 2010;6:775.
8. Collaborative P, Neal B, MacMahon S. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163: 1069-75. (Pubitemid 36548935)
9. Oveisgharan S, Hachinski V. Hypertension, executive dysfunction, and progression to dementia: the Canadian Study of Health and Aging. Arch Neurol 2010;67:187.
10. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1990;27: 1133-42. (Pubitemid 20150025)
11. Kennelly S, Abdullah L, Kenny RA, et al. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients - an open-label trial. Int J Geriatr Psychiatry 2012;27: 415-22.
12. Hajjar I, Brown L, Mack WJ, et al. Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 2012;69: 1632-8.
13. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010;340:65465.
14. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21: 875-86. (Pubitemid 36677151)
15. Ohrui T, Tomita N, Sato-Nakagawa T, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004;63: 1324-5. (Pubitemid 39350046)
16. Rozzini L, Chilovi BV, Bertoletti E, et al. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry 2006;21: 550-5. (Pubitemid 44043756)
17. Hajjar I, Hart M, Milberg W, et al. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr 2009;9:48.
18. Poon IO. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 2008;28: 366-75. (Pubitemid 351328909)
19. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350: 757-64. (Pubitemid 27387202)
20. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046.
21. Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ 1999;161: 501-6. (Pubitemid 29433523)
22. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J 2004;148:52.
23. Mielke M, Rosenberg P, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007;69: 1850-8. (Pubitemid 350071146)
24. Bellew KM, Pigeon JG, Stang PE, et al. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2004;18: 208-13. (Pubitemid 40076150)
25. Rosenberg P, Mielke M, Tschanz J, et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry 2008;16:883.
26. Brunnström H, Gustafson L, Passant U, et al. Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports. Arch Gerontol Geriatr 2009;49: 146-9.
27. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009;110: 1129-34.
28. Kehoe PG, Russ C, McIlory S, et al. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 1999;21:71.
29. Lehmann DJ, Cortina-Borja M, Warden DR, et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 2005;162: 305-17. (Pubitemid 41389712)
30. Miners J, Ashby E, Van Helmond Z, et al. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2007;34: 181-93.
31. Dong YF, Kataoka K, Tokutomi Y, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J 2011;25: 2911-20.
32. Yamada K, Uchida S, Takahashi S, et al. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res 2010;1352: 176-86.
33. Fried LP, Borhani NO, Enright P, et al. The cardiovascular health study: design and rationale. Ann Epidemiol 1991;1: 263-76.
34. Sink KM, Leng X, Williamson J, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 2009;169:1195.
35. Hanes DS, Weir MR. Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. Am J Geriatr Cardiol 2007;16: 175-82.
36. Davies NM, Kehoe PG, Ben-Shlomo Y, et al. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 2011;26: 699-708.
37. Molloy DW, Alemayehu E, Roberts R. Reliability of a standardized mini-mental state examination compared with the traditional mini-mental state examination. Am J Psychiatry 1991;148: 102-5.
38. Molloy DW, Standish TIM. A guide to the standardized Mini-Mental State Examination. Int Psychogeriatr 1997;9: 87-94. (Pubitemid 28045345)
39. O'Caoimh R, Gao Y, McGlade C, et al. Comparison of the quick mild cognitive impairment (Qmci) screen and the SMMSE in screening for mild cognitive impairment. Age Ageing 2012;41: 624-9.
40. O'Caoimh R, Gao Y, Gallagher PF, et al. Which part of the quick mild cognitive impairment screen (Qmci) discriminates between normal cognition, mild cognitive impairment and dementia? Age Ageing 2013;42: 324-30.
41. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDAWork Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34: 939-44. (Pubitemid 14076461)
42. First MB. Diagnostic and statistical manual of mental disorders. DSM IV-4th edn APA 1994: 97-327.
43. Louis ED, Benito-León J, Bermejo-Pareja F. Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES). Neuroepidemiology 2009;33: 286-92.
44. Simon KC, Chen H, Schwarzschild M, et al. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007;69: 1688-95. (Pubitemid 350287125)
45. Rosso S, Landweer E, Houterman M, et al. Medical and environmental risk factors for sporadic frontotemporal dementia: a retrospective case-control study. J Neurol Neurosurg Psychiatry 2003;74: 1574-6.
46. Londos E, Passant U, Gustafson L. Blood pressure and drug treatment in clinically diagnosed Lewy body dementia and Alzheimer's disease. Arch Gerontol Geriatr 2000;30: 35-46. (Pubitemid 30084823)
47. Portet F, Ousset P, Visser P, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006;77: 714-18. (Pubitemid 43837193)
48. Monsell SE, Liu D, Weintraub S, et al. Comparing measures of decline to dementia in amnestic MCI subjects in the National Alzheimer's Coordinating Center (NACC) Uniform Data Set. Int Psychogeriatr 2012;24:1553.
49. Yesavage J. Geriatric Depression Scale. Psychopharmacol Bull 1988;24:709.
50. Rogers D, Pies R. General medical drugs associated with depression. Psychiatry (Edgmont) 2008;5:28.
51. Porter RJ, Gallagher P, Thompson JM, et al. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 2003;182: 214-20. (Pubitemid 36286734)
52. Solfrizzi V, Scafato E, Frisardi V, et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age (Dordr) 2013(2): 441-53.
53. Matthews HP, Korbey J, Wilkinson DG, et al. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000;15: 713-20.
54. Hatazawa J, Shimosegawa E, Osaki Y, et al. Long-term angiotensin- converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke. Stroke 2004;35: 2117-22. (Pubitemid 39129571)
55. Lipsitz LA, Gagnon M, Vyas M, et al. Antihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects. Hypertension 2005;45: 216-21. (Pubitemid 40179963)
56. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147.
57. Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23: 1999-2010. (Pubitemid 34073191)
58. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984.
59. Connor DJ, Sabbagh MN. Administration and scoring variance on the ADAS-Cog. J Alzheimers Dis 2008;15: 461-4.
60. O'Caoimh R, Svendrovski A, Johnston B, et al. Comparison of the Qmci to the SADAS-Cog. J Clin Epidemiol 2013. In press.
61. Hu J, Igarashi A, Kamata M, et al. Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001;276: 47863-8.
62. Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis 2012;30:S251-68.
63. Fournier A, Oprisiu-Fournier R, Serot J-M, et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 2009;9: 1413-31.
64. Kehoe PG, Davies NM, Martin RM, et al. Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis 2013;33: 999-1008.
65. Todd S, McGuinness B, Passmore AP. Designing appropriate clinical trials to assess ACEI use and cognitive decline in older adults with hypertension. Arch Intern Med 2010;170:107.